Floatz logo

INTERFERON-ALFA-2A

Acute Lymphoblastic Leukemia

French Innovative Leukemia Organisationprotein_peptidePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

253 Active assets in the Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
Allogeneic Cd34+-Enriched And Cd45Ra-Depleted Pbscs
Fred Hutchinson Cancer Center
Phase 2/3BBB
Gm-Csf
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Equine Atg
Instituto Nacional de Cancer, Brazil
Phase 3BBB
THIOGUANINE ANHYDROUS
St. Jude Children's Research Hospital
Phase 4BBB
ASPARAGINASE
Centre Hospitalier Universitaire de Nice
Phase 4BB

View all 50 →

Same molecule, other indications

INTERFERON-ALFA-2A is also rated in:

renal cell carcinomaDormant
BB
Indicative ·
71 / 100
View asset →
kidney cancerDormant
B
Indicative ·
62 / 100
View asset →
lymphomaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →